The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: August 2022

Phage resistant Escherichia coli strains developed to reduce fermentation failure
Pharma & Human Health

Phage resistant Escherichia coli strains developed to reduce fermentation failure

AUG 25, 2022
Phage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbes
Gastrointestinal

Phage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbes

AUG 23, 2022
A focus on two critical needs for developing new products in the biotics industry
Pharma & Human Health

A focus on two critical needs for developing new products in the biotics industry

AUG 14, 2022
New needle-free nasal vaccine shows promise for COVID-19
Infectious Disease & AMR

New needle-free nasal vaccine shows promise for COVID-19

AUG 8, 2022